首页> 美国卫生研究院文献>Biomolecules >Chemoinformatic Screening for the Selection of Potential Senolytic Compounds from Natural Products
【2h】

Chemoinformatic Screening for the Selection of Potential Senolytic Compounds from Natural Products

机译:化疗筛选用于从天然产物中选择潜在的森林化合物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cellular senescence is a cellular condition that involves significant changes in gene expression and the arrest of cell proliferation. Recently, it has been suggested in experimental models that the elimination of senescent cells with pharmacological methods delays, prevents, and improves multiple adverse outcomes related to age. In this sense, the so-called senoylitic compounds are a class of drugs that selectively eliminates senescent cells (SCs) and that could be used in order to delay such adverse outcomes. Interestingly, the first senolytic drug (navitoclax) was discovered by using chemoinformatic and network analyses. Thus, in the present study, we searched for novel senolytic compounds through the use of chemoinformatic tools (fingerprinting and network pharmacology) over different chemical databases (InflamNat and BIOFACQUIM) coming from natural products (NPs) that have proven to be quite remarkable for drug development. As a result of screening, we obtained three molecules (hinokitiol, preussomerin C, and tanshinone I) that could be considered senolytic compound candidates since they share similarities in structure with senolytic leads (tunicamycin, ginsenoside Rb1, ABT 737, rapamycin, navitoclax, timosaponin A-III, digoxin, roxithromycin, and azithromycin) and targets involved in senescence pathways with potential use in the treatment of age-related diseases.
机译:细胞衰老是一种细胞条件,涉及基因表达的显着变化和细胞增殖的阻滞。最近,已经提出了实验模型,即消除具有药理学方法的衰老细胞延迟,防止和改善与年龄相关的多种不良结果。从这个意义上讲,所谓的Senoylitic化合物是一类药物,其选择性地消除衰老细胞(SCS)并且可以使用,以便延迟这种不利结果。有趣的是,通过使用化学信息和网络分析来发现第一个森林药物(Navitoclax)。因此,在本研究中,我们通过使用来自来自天然产品(NPS)的不同化学数据库(NotamNat和Biofacquim)来搜索新的Senolytic化合物,这些工具(Forpamnat和Biofacquim)已被证明对药物非常出色发展。作为筛选的结果,我们获得了三种分子(Hinokitiol,Preussomerin C和丹参酮I),其可以被认为是Senolytic复合候选者,因为它们与森冰铅(Tunicamycin,人参苷RB1,ABT 737,Rapamycin,Navitoclax,Timosaponin)分享了Senolytic的化合物候选物。 A-III,地辛,罗西霉素和阿奇霉素)和患有潜在使用用于治疗年龄相关疾病的衰老途径的靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号